Edition:
India

Evotec SE (EVTG.DE)

EVTG.DE on Xetra

22.72EUR
18 Sep 2020
Change (% chg)

€0.10 (+0.44%)
Prev Close
€22.62
Open
€22.60
Day's High
€22.78
Day's Low
€22.59
Volume
30,725
Avg. Vol
728,090
52-wk High
€26.77
52-wk Low
€17.17

Latest Key Developments (Source: Significant Developments)

Evotec And Bioaster Partner To Build Technology And Innovation Hub In Lyon
Monday, 14 Sep 2020 

Sept 14 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC AND BIOASTER PARTNER TO BUILD A TECHNOLOGY AND INNOVATION HUB IN LYON.ACCELERATE AND STRENGTHEN THEIR RESEARCH CAPABILITIES DEDICATED TO FIGHT INFECTIOUS DISEASES.TWO ORGANISATIONS AIM TO PUT FORWARD NEW RESEARCH PROJECTS AGAINST INFECTIOUS DISEASES AND ANTIMICROBIAL RESISTANCE, POTENTIALLY CREATING NEW THERAPIES AND TECHNOLOGIES.TWO ORGANISATIONS AIM TO PUT FORWARD NEW RESEARCH PROJECTS AGAINST INFECTIOUS DISEASES AND ANTIMICROBIAL RESISTANCE, POTENTIALLY CREATING NEW THERAPIES AND TECHNOLOGIES.  Full Article

Evotec And Centogene Expand Collaboration Into Gaucher Disease
Thursday, 20 Aug 2020 

Aug 20 (Reuters) - Evotec Se ::DGAP-NEWS: EVOTEC AND CENTOGENE EXPAND COLLABORATION INTO GAUCHER DISEASE.CENTOGENE AND EVOTEC INTEND TO IDENTIFY NOVEL DISEASE-MODIFYING TARGETS.FIRST TARGET SELECTED FOR DEVELOPMENT OF A THERAPEUTIC CANDIDATE.CENTOGENE CONTRIBUTES ACCESS TO ITS GLOBAL PROPRIETARY RARE DISEASE PLATFORM, EVOTEC WILL LEVERAGE ITS PROPRIETARY IPSC PLATFORM AND DRUG DISCOVERY AND DEVELOPMENT EXPERTISE.  Full Article

Evotec, Novo Nordisk Announce Kidney Disease Collaboration
Tuesday, 18 Aug 2020 

Aug 18 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC AND NOVO NORDISK FORM STRATEGIC ALLIANCE TO DEVELOP NOVEL THERAPIES FOR KIDNEY DISEASES.EVOTEC WILL RECEIVE AN UPFRONT PAYMENT, RESEARCH FUNDING, MILESTONE POTENTIAL ABOVE EUR 150 MILLION PER PROJECT AND TIERED ROYALTIES.EVOTEC CONTRIBUTES ACCESS TO UNIQUE CHRONIC KIDNEY DISEASE ("CKD") PATIENT DATABASES AS WELL AS ITS INTEGRATED MODALITY-AGNOSTIC DRUG DISCOVERY PLATFORM.COLLABORATION INTENDS TO PURSUE MOST RELEVANT HUMAN DISEASE BIOLOGY IN A THERAPEUTIC MODALITY-AGNOSTIC APPROACH TO DEVELOP FIRST-IN-CLASS THERAPEUTICS FOR PATIENTS SUFFERING FROM CKD.EVOTEC AND NOVO NORDISK WILL SHARE RESPONSIBILITIES DURING DRUG DISCOVERY AND PRE-CLINICAL DEVELOPMENT.  Full Article

Evotec Confirms Revenues, Adj EBITDA Guidance, Ups R&D Spending
Wednesday, 12 Aug 2020 

Aug 12 (Reuters) - Evotec SE ::H1 REVENUE ROSE 12 PERCENT TO 231 MILLION EUR.CONTINUED STRONG PERFORMANCE ACROSS ALL BUSINESS LINES DESPITE COVID-19.FULL-YEAR 2020 GUIDANCE FOR REVENUES AND ADJUSTED EBITDA CONFIRMED AND INCREASED FOR UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES TO APPROX. EUR 45 M.GROUP REVENUE GROWTH OF 12% TO EUR 231.0 M.ADJUSTED GROUP EBITDA AMOUNTING TO EUR 47.3 M.NO MATERIAL IMPACT BY COVID-19 PANDEMIC ON OVERALL FINANCIAL AND STRATEGIC DEVELOPMENT SO FAR.SLIGHT DELAYS IN CONCLUSION OF CONTRACTS AND MILESTONE ACHIEVEMENTS.CONTRACT WITH U.S. DEPARTMENT OF DEFENSE TO DEVELOP AND MANUFACTURE MONOCLONAL ANTIBODIES FOR TREATMENT AND/OR PREVENTION OF COVID-19 (AFTER PERIOD-END).  Full Article

Secarna Pharmaceuticals And Evotec Form Strategic Partnership In Antisense Therapy
Wednesday, 5 Aug 2020 

Aug 5 (Reuters) - :DGAP-NEWS: SECARNA PHARMACEUTICALS AND EVOTEC FORM STRATEGIC PARTNERSHIP IN THE FIELD OF ANTISENSE THERAPY.  Full Article

Evotec Subsidiary Wins Contract To Develop COVID-19 Antibodies For U.S. Department Of Defense
Wednesday, 22 Jul 2020 

July 22 (Reuters) - EVOTEC SE ::JUST - EVOTEC BIOLOGICS TO PRODUCE MONOCLONAL ANTIBODY PRODUCTS AGAINST COVID-19 FOR THE DEPARTMENT OF DEFENSE.DEPARTMENT OF DEFENSE ("DOD") AWARDED ITS SEATTLE-BASED SUBSIDIARY, JUST - EVOTEC BIOLOGICS, INC. A CONTRACT VALUED UP TO $ 18.2 M TO DEVELOP AND MANUFACTURE MONOCLONAL ANTIBODIES ("MABS") FOR TREATMENT AND/OR PREVENTION OF COVID-19.  Full Article

Evotec Acquires Site From Sanofi, No Financial Terms Disclosed
Wednesday, 8 Jul 2020 

July 8 (Reuters) - Evotec SE ::EVOTEC ACQUIRES SITE FROM SANOFI AND SECURES CAPACITY FOR LONG-TERM GROWTH.CURRENT BIOPARK EMPLOYEES TRANSFERRING TO EVOTEC.NO FINANCIAL TERMS OF AGREEMENT WERE DISCLOSED.  Full Article

Evotec Enters Nanomedicine Through Partnership With Leon-Nanodrugs
Thursday, 16 Apr 2020 

April 16 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC ENTERS NANOMEDICINE THROUGH STRATEGIC PARTNERSHIP WITH LEON-NANODRUGS.NANO- AND MICROPARTICLES HAVE BROAD APPLICABILITY BOTH ACROSS MODALITIES AND ALONG DISCOVERY AND DEVELOPMENT VALUE CHAIN.BY REFORMULATING MOLECULES, LEON-NANODRUGS' PROPRIETARY TECHNOLOGY ENHANCES EFFICACY AND IMPROVES CLINICAL OUTCOMES.NO FINANCIAL DETAILS OF COLLABORATION WERE DISCLOSED.  Full Article

Evotec Reaches Licensing Agreement With Canada's Pancella
Thursday, 2 Apr 2020 

April 2 (Reuters) - Evotec SE ::EVOTEC EXPANDS ITS IPSC-BASED CELL THERAPY PLATFORM EVOCELLS THROUGH LICENSING AGREEMENT WITH PANCELLA.EVOTEC LICENSES PANCELLA'S STATE-OF--ART IPSC TECHNOLOGIES IACT STEALTH CELL(TM) AND FAILSAFE(TM) FOR USE IN CELL THERAPY.ACCESS TO PANCELLA'S TECHNOLOGY HAS POTENTIAL TO ENABLE SAFE AND OFF--SHELF CELL THERAPY PRODUCTS AND LIFTS EVOTEC'S IPSC-BASED CELL THERAPY PLATFORM ("EVOCELLS") TO NEXT LEVEL.EVOTEC TAKES MINORITY SHAREHOLDING IN PANCELLA.NO FINANCIAL DETAILS OF AGREEMENT WERE DISCLOSED.  Full Article

Evotec Expects 2020 EBITDA at last year's level between 100 to 120 Mln Eur
Thursday, 26 Mar 2020 

March 26 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC SE FISCAL YEAR 2019 RESULTS: EXCELLENT 2019 PERFORMANCE; VERY GOOD OUTLOOK FOR CONTINUED GROWTH 2020.FY REVENUE ROSE 19 PERCENT TO 446.4 MILLION EUR.VERY GOOD OUTLOOK FOR CONTINUED GROWTH 2020.VERY STRONG FINANCIAL RESULTS: 19% INCREASE IN GROUP REVENUES, ADJUSTED GROUP EBITDA UP 29%.2019 GROUP REVENUES UP 19% TO EUR 446.4 M (2018: EUR 375.4 M).ADJUSTED GROUP EBITDA UP 29% TO EUR 123.1 M (2018: EUR 95.5 M).FINANCIAL GUIDANCE 2020 - CONTINUED STRONG ORGANIC GROWTH.GIVEN CURRENT GLOBAL INSECURITIES SURROUNDING COVID-19 PANDEMIC, A LIKELY NEGATIVE IMPACT IS ALREADY ESTIMATED WITHIN INTRODUCED GUIDANCE FOR REVENUES AND ADJUSTED EBITDA.IT IS NOT POSSIBLE TO PRECISELY PREDICT OR QUANTIFY POTENTIAL IMPACT ON REVENUE AND FINANCIAL PERFORMANCE AT THIS EARLY STAGE.THIS UNCERTAINTY ALSO EXPLAINS BROADER THAN USUAL RANGES.EVOTEC WILL CONTINUE TO VERY CLOSELY MONITOR FURTHER DEVELOPMENT OF THIS EXCEPTIONAL SITUATION AND UPDATE ON GUIDANCE IN CASE SITUATION CHANGES MATERIALLY..2020 GROUP REVENUES EXPECTED TO BE IN A RANGE OF EUR 440 - 480 M (2019: EUR 446.4 M INCLUDING REVENUES FROM MATERIAL RECHARGES ACCORDING TO IFRS 15).ADJUSTED GROUP EBITDA EXPECTED TO BE ON SIMILAR LEVEL AS IN 2019, EUR 100 - 120 M (2019: EUR 123.1 M).UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES EXPECTED TO BE APPROX. EUR 40 M (2019: EUR 37.5 M)."ACTION PLAN 2022" ON TRACK, DESPITE MASSIVE GLOBAL INSECURITIES.  Full Article

BRIEF-Evotec Acquires Site From Sanofi, No Financial Terms Disclosed

* EVOTEC ACQUIRES SITE FROM SANOFI AND SECURES CAPACITY FOR LONG-TERM GROWTH